Estrogen (E) deficiency associated with the menopause is the major cause of bone loss in aging women. However, men also lose significant amounts of bone with age, but they do not have the equivalent of menopause, and serum total testosterone (T) and E levels decline only marginally with age in men. Thus, it has been difficult to attribute bone loss in aging men to either T or E deficiency. Here, we show in a population-based, age-stratified sample of 346 men, aged 23-90 yr, that serum total T and E (estradiol plus estrone) levels decreased over the life span by 30% and 12%, respectively, but bioavailable (or nonsex hormone-binding globulin-bound) T and E levels decreased by 64% and 47%, respectively. In these men and in a parallel cohort of 304 women, aged 21-94 yr, serum PTH increased 84% and 64% over the life span, and urinary N-telopeptide of type I collagen (NTx) excretion, a bone resorption marker, increased 77% and 80% between age 50 -85 yr in the men and women, respectively. By univariate analyses, serum bioavailable T and E levels correlated positively with bone mineral density (BMD) at the total body, spine, proximal femur, and distal radius and negatively with urinary NTx excretion in men and women. Urinary NTx excretion was also negatively associated with BMD in both sexes. By multivariate analyses, however, serum bioavailable E level was the consistent independent predictor of BMD in both men and postmenopausal women. Thus, bioavailable E levels decline significantly with age and are important predictors of BMD in men as well as women. These studies suggest that in contrast to traditional belief, age-related bone loss may be the result of E deficiency not just in postmenopausal women, but also in men. (J Clin Endocrinol Metab 83: 2266 -2274, 1998) A LTHOUGH osteoporosis is more common in women, men also incur substantial bone loss with aging (1, 2), and elderly men have age-specific hip fracture and vertebral fracture rates that are at least half those in women (3). Indeed, recent estimates are that of the $13.8 billion cost to the U.S. health care system attributed to osteoporosis each year, approximately $2.7 billion is related to fractures in men (4). Thus, osteoporosis in men is a significant problem both clinically and economically and is likely to increase in scope as the population ages.
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Estrogen (E) deficiency has clearly been identified as a major risk factor for osteoporosis in women, and the effects of E on the skeleton have been the subject of intensive investigation. Recent evidence indicates that E deficiency may be responsible not only for the early postmenopausal phase of rapid bone loss, but also for the late slow phase of bone loss associated with aging. The latter had been attributed at least in part to an age-related increase in bone turnover, due largely to increases in serum PTH levels with aging (5-7). E therapy of elderly postmenopausal women, however, appears to prevent the secondary hyperparathyroidism and increased bone turnover associated with aging (7, 8) . This has led to the hypothesis that the extraskeletal effects of E, namely on intestinal calcium absorption (9, 10) , renal calcium handling (11, 12) , and perhaps direct effects on PTH secretion (13) , may be responsible for preventing the age-related increase in serum PTH and in bone turnover in late postmenopausal women treated with E (14) .
Despite the fact that men do not have the equivalent of menopause and that serum total testosterone (T) levels decrease only marginally with age (15) (16) (17) , men have substantial age-related decreases in bone mineral density (BMD) in both cross-sectional (18) and longitudinal (19) studies. Moreover, previous epidemiological studies assessing the relationship between serum total T levels and BMD have generally found either no relationship (17, 20) or even a negative association between total T levels and BMD in aging men (21) . Thus, the absence of substantial decreases in serum total T levels in aging men has led to the belief that T does not play a major role in bone loss in aging men.
Recent studies have suggested instead the possibility that, as in women, E may play a key role in regulating bone turnover in men. Smith et al. (22) described a male with homozygous mutations in the E receptor gene who, even in the presence of normal T and free T levels, had unfused epiphyses and marked osteopenia, along with elevated indexes of bone turnover. Subsequently, Morishima et al. (23) and Carani et al. (24) reported clinical findings in two males with homozygous mutations of the gene that codes for the enzyme, aromatase, which is responsible for the conversion of androgens to E. In both instances, BMD was significantly reduced, and bone turnover markers were markedly elevated despite normal T levels. Treatment with T did not significantly affect bone metabolism in one patient (24) , whereas treatment with E markedly increased BMD in both patients (24, 25) . Finally, a recent epidemiological study by Slemenda et al. (21) found that serum estradiol (E 2 ), but not T, levels were positively associated with BMD in men over age 65 yr.
Despite these findings, a major conceptual problem with attributing age-related bone loss in men to E deficiency is that, as in the case of total T levels, serum total E levels decline only marginally with age in men (15) . However, there are several important limitations of previous studies attempting to define the relationship of T or E to BMD in men. First, most have studied subjects in a narrow age range, such as elderly men (20, 21, 26) . Second, they have failed to measure levels of circulating bioavailable sex steroids. The bioavailable sex steroids comprise the fractions that are free or associated with albumin in the circulation (27) (28) (29) (30) , and it is these fractions that have rapid access to target tissues (31, 32) . In contrast, the fraction bound to sex hormone-binding globulin (SHBG) does not have free access to target tissues. As SHBG levels increase with age in men (33, 34) , measurement of total T or E levels does not accurately reflect the actual levels of these steroids available to tissues. Moreover, although several studies have measured circulating free T and E levels (21, 26) , the free fraction constitutes only 1-3% of the total circulating sex steroids (30) , and failure to account for the 35-55% of the circulating steroids bound to albumin vastly underestimates the proportion available to target tissues.
In the present study, we addressed these limitations in several ways. First, we defined the age-related changes in circulating bioavailable T and E levels in a population-based, age-stratified sample of men, aged 23-90 yr (n ϭ 346). Next, we assessed age-related changes in serum PTH and in markers of bone turnover in these men and related these to BMD and the sex steroids. We also assessed the relative importance of bioavailable T vs. E levels in determining BMD in men by multivariate analyses. Finally, we performed similar studies in a parallel cohort of 304 women so that these relationships in aging men vs. women could be compared.
Subjects and Methods

Study subjects
Subjects were recruited from an age-stratified random sample of Rochester, MN, men and women that were selected using the medical records linkage system of the Rochester Epidemiology Project (35) . Over half of the Rochester population is identified annually in this system, and the majority are seen in any 3-yr period. Thus, the enumerated population approximates the underlying population of the community, including both free-living and institutionalized individuals. Altogether 1138 men and 938 women aged 20 yr and over were approached, but 239 men and 126 women were ineligible (among the men, 109 were demented and could not give informed consent, 13 were radiation workers, 91 died before contact, 25 were debilitated due to terminal cancer, and 1 was unable to participate due to pending legal action; among the women, 89 were demented, 11 were pregnant, 9 were radiation workers, 8 were participants in an ongoing clinical trial of osteoporosis prophylaxis, and 9 died before they could be contacted). Of the 899 eligible men, 348 participated and provided full study data, although 2 were excluded from analysis because 1 was receiving T therapy and 1 had inexplicably high (into the range of premenopausal women) E 2 and estrone (E 1 ) levels. Of the 812 eligible women, 351 participated and provided full study data, although 47 of the 213 postmenopausal women were receiving E replacement therapy and were excluded from this analysis. Thus, the total number of subjects included in this analysis was 650 (346 men and 304 women). All but 13 men and 3 women were Caucasian, reflecting the ethnic composition of the population (96% white in 1990). The men ranged in age from 23-90 yr, and the women ranged in age from 21-94 yr.
As this sample of subjects was population based, the overall results are applicable to the general population of men and women in the community. However, we also performed subset analyses in normal subjects, excluding those with rheumatoid arthritis (4 men and 5 women), Paget's disease (5 men), gastrointestinal resection (11 men and 1 woman), significant renal insufficiency (defined as serum creatinine Ͼ2 mg/dL, 6 men), chronic obstructive pulmonary disease (14 men and 3 women), prostate cancer or bilateral orchidectomies (12 men), premature menopause (at Ͻ35 yr of age; 1 woman), or current therapy with corticosteroids (7 men and 7 women), thiazide diuretics (21 men and 33 women), anticonvulsants (2 men and 2 women), or oral contraceptives (28 premenopausal women). After all of these exclusions, the subset of normal men and women consisted of 280 and 231 subjects, respectively.
Study protocol
BMD (grams per cm
2 ) was determined for the total body, spine (L2-L4), proximal femur (total), and middistal radius using dual energy x-ray absorptiometry with the Hologic QDR2000 instrument (Hologic, Waltham, MA) using software version 5.40. As we did not specifically exclude subjects with spinal osteoarthritis or aortic calcification, which can confound the BMD measurement (36), we assessed the midlateral instead of the antero-posterior spine, which largely excludes these confounders from the scanning field. The coefficients of variation (CVs) for the total body, lateral spine, femur, and radius were 0.8%, 2.1%, 1.8%, and 1.7%, respectively.
Fasting state serum samples were obtained between 0800 -0900 h, and a 24-h urine collection was completed. All samples were stored at Ϫ70 C until analyzed.
Laboratory methods
Fasting serum samples were assayed by RIA for total T (Diagnostic Products Corp., Los Angeles, CA; interassay CV, 11%), E 2 (Diagnostic Systems Laboratories, Webster, TX; interassay CV, 11%), E 1 (Diagnostic Systems Laboratories; interassay CV, 9%), and SHBG (Wien Laboratories, Succasunna, NJ; interassay CV, 7%). In addition, the non-SHBGbound (bioavailable) fractions of total T, E 2 , and E 1 were measured using a modification of the techniques of O'Connor et al. (27) and Tremblay et al. (28) . Briefly, tracer amounts of 3 H-labeled T, E 2 , or E 1 were added to serum aliquots. An equal volume of saturated solution of ammonium sulfate (final concentration, 50%) was added to precipitate SHBG with its bound steroid. Separation of the SHBG fraction was performed by centrifugation at 1100 ϫ g for 30 min at 4 C. The percentage of labeled steroid remaining in the supernatant (the free and albumin-bound fractions) was then calculated. The bioavailable steroid concentration was obtained by multiplying the total steroid concentration, as determined by RIA, by the fraction that was non-SHBG bound. Free T was measured by RIA using a T analog with low affinity for SHBG and albumin (Diagnostic Systems Laboratories; interassay CV, 10%). Serum dehydroepiandrosterone sulfate (DHEAS) was measured by RIA (Diagnostic Products Corp.; interassay CV, Ͻ8%). Serum LH and FSH were measured by immunoradiometric assays (Diagnostic Products Corp.; interassay CV, 14% for LH and 11% for FSH).
Serum intact PTH was measured by immunochemiluminometric assay (37) (interassay CV, 14%). Bone formation was assessed by serum osteocalcin, measured by RIA using antibody G12 (interassay CV, Ͻ6%) (5), as well as by serum bone alkaline phosphatase (BAP), measured by enzyme-linked immunosorbent assay (5) (ELISA; interassay CV, Ͻ11%), and serum carboxyl-terminal propeptide of type I collagen (PICP), also measured by ELISA (Prolagen-C, Metra Biosystems, Mountain View, CA; interassay CV, Ͻ7%). Bone resorption was evaluated by measurement of 24-h urinary levels of the N-telopeptide of type I collagen (NTx) and free deoxypyridinoline (f-Dpd), both assessed as nanomoles per L glomerular filtrate. NTx and f-Dpd were measured by ELISA kits (Os-teomark, Ostex, Seattle, WA; interassay CV, 10%; and Pyrilinks-D, Metra Biosystems, Mountain View, CA; interassay CV, 14%). The glomerular filtration rate was assessed by creatinine clearance.
Statistical analysis
Pearson correlations were used to summarize relationships between the various continuous variables. Log transformations were used on highly skewed variables. When appropriate, Spearman correlations were used. The percent change from age 25-85 yr was estimated from predictions using a loess model in S-plus (38) , using the following formula: percent change ϭ [(value at age 85 yr Ϫ value at age 25 yr)/value at age 25 yr] ϫ 100. The smoother function was also used as a means to visually explore the data in the various plots. Stepwise model selection was used to determine the relationship of sex steroid variables and bone turnover markers with BMD. Higher ordered terms and interactions were checked, but were only included if they made a meaningful change to the model. Finally, model assumptions were checked by examination of the model residuals. Table 1 shows the correlation coefficients between BMD and age in the men and women. In this cross-sectional analysis, BMD declined significantly with age in both sexes at all sites, and Table 1 also indicates the percent decrease from age 25-85 yr in BMD at the various sites. Thus, at all sites, the percent decrease in BMD was approximately twice as great in the women as it was in the men. Table 1 also shows the age-related changes in serum sex steroid levels in the men and women. Between age 25-85 yr, the decline in bioavailable T was almost twice that in total T in both sexes, and bioavailable T decreased by approximately 64% and 28% in the men and women, respectively (Table 1 and Fig. 1, A and B) . In the men, total E (E 2 plus E 1 ) declined only marginally with age, whereas bioavailable E decreased by 47% (Table 1 and Fig. 2, A and B) . In contrast, total and bioavailable E levels decreased similarly in the women. For simplicity, we have presented the data for total and bioavailable E 2 plus E 1 , although E 2 and E 1 individually showed similar changes. As expected, there was a precipitous drop in serum total and bioavailable E levels in the women around the time of the menopause, whereas there was a gradual, age-related decrease in bioavailable E levels in the men ( Table 1 for correlation coefficients with age.
Results
Age-related changes in BMD and serum sex steroids
2, A and B)
. There was also a marked difference between sexes in changes in SHBG with age; SHBG increased by more than 2-fold over the life span in the men, whereas it was virtually unchanged in the women (Table 1 and Fig. 3) . Thus, the greater decrease in bioavailable T and E in the men was explained in large part by the age-related increase in SHBG levels. Finally, serum DHEAS levels also decreased significantly with age in both sexes (Table 1) . We also assessed whether in addition to the bioavailable sex steroid measures, other indexes of bioavailable or free sex steroids decreased similarly with age in the men and women (Table 1) . Thus, the age-related decreases in the molar ratios of T to SHBG and E to SHBG were comparable to the decreases in directly measured bioavailable T and E, respectively. In addition, the free T level, which represents the T fraction not bound to either SHBG or albumin, decreased with age in a manner similar to bioavailable T in both sexes.
The age-related decreases in sex steroids were accompanied by parallel increases in serum LH and FSH levels ( Table  1) . Of note, serum LH in the men did not correlate with serum total T or E levels (r ϭ 0.03 and Ϫ0.04, respectively), but was inversely correlated with serum bioavailable T and E levels (r ϭ Ϫ0.35 and r ϭ Ϫ0.29, respectively; both P Ͻ 0.001). Similarly, serum FSH in the men was only weakly inversely correlated with serum total T and E levels (r ϭ Ϫ0.11; P ϭ 0.05; and r ϭ Ϫ0.15; P ϭ 0.01, respectively), but showed a strong negative association with serum bioavailable T and E levels (r ϭ Ϫ0.46 and r ϭ Ϫ0.35, respectively; both P Ͻ 0.001). In contrast, in the women, serum LH and FSH were both inversely associated with serum total and bioavailable E levels (r ϭ Ϫ0.19 and r ϭ Ϫ0.21, respectively; both P Ͻ 0.001 for total and bioavailable E vs. LH; and r ϭ Ϫ0.54 and Ϫ0.55, respectively; both P Ͻ 0.001 for total and bioavailable E vs. FSH). However, neither serum LH nor FSH was correlated with T levels in the women (data not shown). Figure 4 , A-C, shows the changes in serum PTH, serum osteocalcin, and urinary NTx excretion as a function of age in the men and women. In these cross-sectional data, serum PTH increased similarly with age in both sexes; over the life span, the percent increase in serum PTH was 84% in the men and 64% in the women. Serum osteocalcin and urinary NTx excretion decreased with age in the men up to approximately age 50 yr and increased with age thereafter. Similarly, serum osteocalcin and urinary NTx decreased with age in the premenopausal women and increased with age in the postmenopausal women. Table 2 shows the correlation coefficients between all of the measured bone turnover markers and age in the men and women. Serum BAP had an agerelated pattern similar to that of serum osteocalcin, although none of the individual correlation coefficients was statistically significant. Serum PICP decreased with age in the men up to age 50 yr and in the premenopausal women, and then showed little or no change with age in the men over age 50 yr or in the postmenopausal women. Urinary f-Dpd excretion showed age-related changes similar to those for urinary NTx excretion. Table 3 shows the results of the univariate analyses relating BMD at the various skeletal sites to the sex steroid and DHEAS levels in the men and women. In the men, serum total T levels did not correlate with BMD at any site, except weakly at the radius. In contrast, serum bioavailable T levels were significantly correlated with BMD at all sites in the men. In the women, serum total and bioavailable T levels were equally correlated with BMD at the various sites. Serum total and bioavailable E levels were correlated with BMD at the various sites in the men, although, as for T, the correlations in the men were considerably stronger for bioavailable as opposed to total E. In contrast, serum total and bioavailable E levels were equally correlated with BMD in the women. Table 1 for correlation coefficients with age.
Age-related changes in serum PTH and bone turnover markers
Relationship among BMD, sex steroids, and bone turnover
FIG. 4. Serum PTH (A), serum osteocalcin (B)
, and urinary NTx (C) levels as a function of age among an age-stratified sample of Rochester men (solid lines, squares) and women (dashed lines, circles). Serum PTH increased significantly with age (r ϭ 0.30; P Ͻ 0.001 for the men and women). The curves for serum osteocalcin and urinary NTx were biphasic (see text for details and Table 2 for correlation coefficients).
Serum DHEAS levels were also correlated with BMD in both sexes. Table 4 shows the results of the univariate analyses relating BMD at the various sites to serum PTH and the bone turnover markers. Serum PTH was inversely associated with BMD at all sites in men and women, except for total body BMD in the men. All of the bone turnover markers, except for serum PICP, were generally inversely correlated with BMD at the various sites, although the associations between the turnover markers and BMD were much stronger in the women than in the men. Finally, the sex steroids, particularly the bioavailable fractions, were inversely correlated with bone resorption markers (r ϭ Ϫ0.20 and r ϭ Ϫ0.19, respectively; both P Ͻ 0.001 for bioavailable T vs. urinary NTx in the men and women; and r ϭ Ϫ0.12; P ϭ 0.02 and r ϭ Ϫ0.29; P Ͻ 0.001 for serum bioavailable E vs. urinary NTx in the men and women, respectively). Serum osteocalcin was not correlated with bioavailable T in men or women, but did correlate inversely with bioavailable E in the women (r ϭ Ϫ0.26; P Ͻ 0.001). As the associations between sex steroids, PTH, and bone turnover markers were similar at the various skeletal sites, we selected the proximal femur as a representative site to further explore the relationships between BMD and the sex steroids and bone turnover markers as a function of age and menopausal status. As shown in Table 5 , serum total T was negatively correlated with proximal femur BMD in the men under age 50 yr. Serum E, particularly bioavailable E levels, were positively correlated with BMD in the younger and in the older men. Serum total and bioavailable T levels were correlated with proximal femur BMD in the pre-and postmenopausal women. Neither serum total nor bioavailable E levels correlated with proximal femur BMD in the premenopausal women, but were strongly associated with BMD in the postmenopausal women. Proximal femur BMD was inversely correlated with bone turnover markers in the postmenopausal women and in the men over age 50 yr, but was only weakly related or had no relationship to the turnover markers in the premenopausal women or men under age 50 yr.
To assess the relative contributions of androgens vs. E in determining BMD, multivariate models were constructed in which BMD was the dependent variable, and serum bioavailable T and E, nonbioavailable (i.e. SHBG-bound) T and E, and DHEAS were the independent variables. Table 6 shows the results of the analysis at the proximal femur. The results of the analysis were similar in the men under and over age 50 yr and are therefore presented for the group as a whole. However, the relationships were significantly different in the pre-vs. postmenopausal women and are therefore presented separately for both groups. In the men, serum bioavailable E was the most important sex steroid predicting proximal femur BMD. After this had entered the model, neither serum T nor DHEAS was an independent predictor. Of note, once bioavailable E had entered the model, nonbioavailable E was negatively associated with proximal femur BMD. In the postmenopausal women, serum bioavailable E was also the most important sex steroid predicting BMD, although DHEAS also entered the model after bioavailable E. In contrast, in the premenopausal women, serum bioavailable T, rather than E, was an independent predictor of BMD.
As the effects of sex steroids on BMD are probably mediated at least in part by changes in bone turnover, we repeated the above multivariate analysis after adjusting for the effects of bone turnover on BMD. Thus, urinary NTx and serum osteocalcin were either allowed to enter or forced into the models, and residual effects of the sex steroids were then examined. In these analyses, even after adjusting for the relationship between bone turnover markers and BMD, serum bioavailable E remained a significant independent predictor of BMD in the men and the postmenopausal women, and bioavailable T remained significant in the premenopausal women (data not shown). The entire analysis was repeated at the other sites in the men and the women, with similar results at the total body and lateral spine in the men and the women and at the distal radius in the women. At the distal radius site in the men, both bioavailable T and E were approximately equally correlated with BMD (Table 3) , and which was picked in the multivariate model depended on whether the bone turnover markers were included in the model; in the absence of the bone turnover markers, bioavailable T was picked as the more important predictor of radius BMD, whereas if the bone turnover markers were included, bioavailable E was selected.
Finally, as the above analyses were performed in the entire population-based sample of men and women, we repeated the analyses in the strictly defined normal subjects (see Materials and Methods) with the same results in terms of predictors of BMD as those shown in Table 6 for the entire cohort.
Discussion
In women, E deficiency is the major cause of early postmenopausal, and perhaps also the subsequent phase of late postmenopausal, slow bone loss (7, 8, 14) . This leads to a conceptual problem in defining the cause of age-related bone loss in men because men do not have a menopause and because serum levels of total T or E decline only minimally with age (15) (16) (17) . Moreover, previous epidemiological studies have found either no association (17, 20) or even a negative association between serum total T levels and BMD in aging men (21) . The latter study did note a positive association between serum E 2 levels and BMD in elderly men (21) , but as serum total E levels remain relatively constant over the life span in men (15) , it was difficult to attribute bone loss with aging in men to E deficiency. Thus, with the exception of clearly hypogonadal men, age-related bone loss in men had been attributed principally to factors other than sex steroid deficiency (39) . Our data for serum bioavailable E and T levels may help to resolve these issues. By studying subjects over the broad age range of 23-90 yr and by directly measuring bioavailable T and E levels, we were able to demonstrate that elderly men have marked age-related decreases in both serum bioavailable T and E levels. Moreover, although both serum bioavailable T and E levels were correlated with BMD, serum bioavailable E was found to be the consistent independent predictor of BMD by multivariate analysis. Taken together, our data are consistent with the hypothesis that age-related decreases in E availability could at least in part account for the decrease in BMD with age in men. Our findings are also consistent with those of Greendale et al. (40) , who recently reported that in elderly men and women, serum bioavailable E was more strongly associated with BMD than was bioavailable T. However, as they only studied elderly subjects, the relationship of sex steroids to age-related decreases in BMD were unclear. Despite these findings, however, further longitudinal and direct intervention studies are clearly needed to quantify the relative contributions of T vs. E in determining age-related bone loss in men.
In contrast to women, who have a precipitous decrease in serum E levels around the time of the menopause, the agerelated decrease in serum bioavailable T and E levels is much more gradual in aging men. This would suggest that the dramatic decrease in serum E levels at the time of the menopause in women triggers a rapid phase of bone loss, which is absent in men. Indeed, this probably accounts for our observation that the percent decrease in BMD over the life span at all sites was approximately twice as great in women as it was in men. However, men made acutely hypogonadal by orchidectomy also have a rapid phase of bone loss (39); as both T and E levels fall to extremely low levels after orchidectomy, these studies do not address the issue of the relative contributions of T vs. E in mediating postorchidectomy bone loss. Nonetheless, the similar relationships between bioavailable E and BMD noted in this study in both men and postmenopausal women suggest a fundamentally similar role for E in determining BMD in both sexes. We also found, however, that E levels did not predict BMD in premenopausal women, suggesting that these women all had E levels above some threshold such that variations in E levels were no longer associated with BMD.
These studies also demonstrate that whereas serum total and bioavailable E levels decrease in women principally because of a decrease in ovarian E production, they decrease in men principally because of an age-related increase in SHBG levels. Indeed, although serum SHBG levels increased markedly in the men, they changed little over the life span in the women. Similar gender differences in SHBG levels with aging have been reported by GoodmanGruen et al. (41) in a study of men and women, aged 50 -82 yr. The reasons for this difference in changes in serum SHBG with age between men and women are unclear. However, the biological relevance of the decrease in bioavailable sex steroids in the men is supported by the much stronger inverse correlations in these subjects between bioavailable T and E levels and LH and FSH levels compared with the relationship between total T and E levels and gonadotropin levels.
Our findings are also consistent with previous observations in E receptor-negative (22) and aromatase-deficient males (23) (24) (25) , which had suggested an important role for E in skeletal metabolism in men. Moreover, in a study of aged male rats, Vanderschueren et al. (42) found no differences in the effects of orchidectomy or treatment with the aromatase inhibitor, vorazole, on the decrease in bone density, suggesting that the aromatization of androgens to estrogens was playing a major role in skeletal maintenance in the male rats.
We also assessed serum PTH levels and biochemical markers of bone turnover and found, as we (5-7) and others (43) have previously reported, that there is a significant agerelated increase in serum PTH levels in both men and women. Our findings also indicate that bone formation and resorption markers decreased in men between 20 and 50 yr of age and in premenopausal women, probably reflecting higher bone turnover in young individuals in the third decade who are completing the phase of skeletal consolidation. After age 50 yr in the men and in postmenopausal women, however, the bone resorption markers (urinary NTx and f-Dpd) increased significantly with age, as we have shown previously for women (44) . Of the bone formation markers, only serum osteocalcin showed a consistent increase with age in both sexes. In general, bone turnover markers showed inverse correlations with BMD in the men and the women, although the relationships were stronger in the women. However, even adjusting for effects of bone turnover, serum bioavailable E levels remained significant predictors of BMD in the men and the postmenopausal women. The persistent relationship between BMD and serum bioavailable E (even after adjusting for the effects of bone turnover) noted in our study may be due to less variability in the bioavailable E measurement than in the measurement of the bone turnover markers. Alternatively, these findings could be due to the fact that E may be affecting both bone resorption and formation, whereas markers assessing these processes separately, such as osteocalcin and NTx, may not have as strong a predictive value. Finally, our data show that circulating total and bioavailable E levels are approximately twice as high in men as those in postmenopausal women. In recent studies, we have demonstrated that reduction of the low levels of serum E in a group of late (mean age, 69 yr) postmenopausal women to near undetectable levels by the administration of letrozole, an aromatase inhibitor that blocks the conversion of weak androgens to E in adipose and other peripheral tissues, increased bone resorption by about 15% (45) . Thus, it is likely that the circulating levels of E in aging men have significant effects on bone turnover, although similar studies using aromatase inhibitors are needed to establish a causal relationship between E and bone turnover in aging men as well as the relative contributions of E vs. T in determining rates of bone turnover in men.
Our findings may also have practical, clinical implications for the prevention and treatment of osteoporosis in aging men. As noted earlier, we (7, 8) and others (46) have shown that E treatment of elderly women can prevent or reverse the age-related increase in bone turnover and prevent bone loss (47) . As we found that serum bioavailable E levels decreased markedly in aging men and also correlated with BMD, it is plausible that treatment of elderly men with E or selective E receptor modulators, such as raloxifene, may reduce bone turnover and prevent bone loss in aging men. Indeed, a preliminary study by Taxel et al. (48) found that E treatment of elderly men (2 mg/day micronized 17␤-estradiol) for 9 weeks significantly reduced markers of bone resorption by 11 to 27%. Moreover, as T therapy, in fact, represents combined therapy with T and E (due to the aromatization of T to E), T therapy of aging men may well have significant beneficial effects on BMD and bone turnover, as suggested by several preliminary studies (49 -51) . Indeed, one recent study of T therapy of eugonadal men with spinal osteoporosis found that the increase in spine BMD after T therapy correlated with the T-induced increase in serum E 2 levels, but not with increases in the serum T levels themselves (51) .
Although our data indicate an important role for E in the regulation of skeletal metabolism in men, T clearly also has significant skeletal effects. Osteoblasts contain androgen receptors (52), and T is almost certainly responsible for the sexual dimorphism of the skeleton that develops after puberty and probably also stimulates periosteal growth of cortical bone (53) . It is, therefore, of interest that at the distal radius site in the men, bioavailable T and E levels were approximately equally correlated with BMD, and which was picked in the multivariate model depended on whether the bone turnover markers were included in the model. This would suggest that at this predominantly cortical site, bioavailable T may have a greater effect on BMD in the men than at the other sites assessed, although more work is clearly needed to address this issue. Finally, serum bioavailable T was a significant independent predictor of BMD in the premenopausal women, suggesting that when T levels are low, as in this group, variations in these levels are significantly related to BMD. Conversely, when both T and E levels are low (as in the case of postmenopausal women), or when T levels are relatively high but E levels are low (as in the case of men), the variations in E levels are more important predictors of BMD.
In summary, these data indicate that aging men have significant decreases in bioavailable sex steroid levels, which correlate with BMD. Moreover, serum bioavailable E levels predict BMD in men and in postmenopausal women, suggesting fundamentally similar roles for E in skeletal metabolism in both sexes. We also demonstrate very similar changes in serum PTH and bone turnover in aging men and women. Taken together with the recent data from E receptornegative and aromatase-deficient males (22) (23) (24) (25) , our findings suggest the need to reevaluate the traditional belief that the effects of sex steroids on the male skeleton are almost entirely due to T. Additional longitudinal studies should be made to compare the effects of T and E on bone and calcium homeostasis in men and to test the hypothesis that E deficiency is a major cause of bone loss in aging men.
